Source comparison
NAD+ Precursor vs MOTS-C Monotherapy vs Combination Protocol: Research Outcomes
NAD+ Precursor (NMN/NR) Alone SIRT1/SIRT3 activation → PGC-1α deacetylation → mitochondrial biogenesis +12–18% (rodent models) Significant increase (40–60% in aged tissue) +15–22% in endurance metrics Plateaus unless paired with AMPK activation Builds capacity
This comparison does not assign a generated winner or score.
- NAD+ Precursor (NMN/NR) Alone
- SIRT1/SIRT3 activation → PGC-1α deacetylation → mitochondrial biogenesis
- +12–18% (rodent models)
- Significant increase (40–60% in aged tissue)
- +15–22% in endurance metrics
- Plateaus unless paired with AMPK activation
- Builds capacity but doesn't fully activate substrate utilization. Metabolic improvements taper after initial gains
- MOTS-C Alone
- Nuclear translocation → AMPK activation → GLUT4/CPT1A upregulation
- +35–43% (diet-induced obesity models)
- Minimal. Activates existing mitochondria
- +18–28% in VO2max proxies
- Effect diminishes without mitochondrial expansion
- Activates pathways effectively but limited by existing mitochondrial density. Benefits plateau as infrastructure becomes limiting
- Stacked NAD+ + MOTS-C
- Dual pathway: sirtuin-mediated biogenesis + AMPK substrate delivery
- +48–62% (preliminary observational data)
- Sustained increase with enhanced function
- +35–45% across multiple parameters
- Sustained beyond 16 weeks in combination protocols
- Closes the regulatory loop. Mitochondrial expansion paired with metabolic demand signaling produces sustained improvements monotherapy can't maintain
- Exercise + NAD+
- Endogenous AMPK activation + sirtuin pathway
- +28–35%
- Moderate increase
- +30–40%
- Highly durable if training continues
- Effective but requires ongoing intervention. MOTS-C may replicate exercise's AMPK effects without training volume